Compare Novavax Inc (NVAX) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Novavax Inc trades at $11.68 (market cap $1.82B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.76 (market cap $2.03B). The key difference: Novavax Inc and Direxion Daily 20 Year Treasury Bull 3X Shares are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| NVAX | TMF | |
|---|---|---|
Market Cap | $1.82B | $2.03B |
Volume | 6,198,505 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $12.56 | $44.14 |
52-Week Low | $6.22 | $25.19 |
Typical Hold Time | 59 Days | 28 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
TMF trades at $25.23, down 0.51% with bearish technical signals from moving averages. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest. Key support sits at $24-25 while resistance levels are at $25-26. RSI readings below 20 suggest potential oversold conditions despite the bearish trend.
As a leveraged Treasury ETF, TMF faces interest rate sensitivity and market volatility risks. The bearish technical outlook and Federal Reserve policy uncertainty create headwinds, though oversold conditions may present tactical opportunities for investors anticipating rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
